News

Tiziana Life Sciences Celebrates Major Milestone at Nasdaq

Tiziana Life Sciences Celebrates Major Milestone at Nasdaq

Tiziana Life Sciences Celebrates Major Milestone at Nasdaq

BOSTON – Tiziana Life Sciences, Ltd. (NASDAQ: TLSA), a pioneering biotechnology firm renowned for its innovative immunomodulation therapies, proudly took another significant step as its Executive Chairman and Founder, Gabriele Cerrone, rang the Nasdaq Closing Bell recently, an event that shines a spotlight on the Company's ambitious efforts in the realm of groundbreaking medical treatments.

The Significance of the Nasdaq Bell Ringing

The Nasdaq bell ringing ceremony serves as a prestigious celebration of Tiziana's remarkable journey in the biopharmaceutical landscape, demonstrating the hard work and commitment of its dedicated team and stakeholders. Gabriele Cerrone expressed his pride in this achievement, stating, "Ringing the Nasdaq Closing Bell is truly a momentous occasion for Tiziana. It is a reflection of our team’s unwavering dedication towards transforming the standards of care in immunomodulation therapies. We look forward to the future as we continue our quest to address critical medical challenges that remain unmet."

Advancements in Innovative Treatments

As Tiziana Life Sciences continues to propel its innovative pipeline forward, the Company announced noteworthy achievements, including the initiation of its Phase 2 clinical trial focusing on Alzheimer’s disease. The lead candidate, intranasal foralumab, has displayed promise as a fully human anti-CD3 monoclonal antibody that aims to provide enhanced safety and efficacy, diverging from traditional intravenous methods.

About Intranasal Foralumab

Foralumab represents a revolutionary treatment option designed to stimulate T regulatory cells through intranasal delivery. With early-phase clinical studies yielding positive outcomes, Tiziana has successfully dosed multiple patients suffering from Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), with encouraging signs of disease stabilization or improvement noted. This innovative approach to immunotherapy distinguishes Foralumab as the only fully human anti-CD3 monoclonal antibody currently in this phase of clinical development.

Commitment to Address Unmet Medical Needs

Tiziana Life Sciences is passionate about redefining treatment paradigms for neurodegenerative diseases like multiple sclerosis, Alzheimer's, and others through its unique delivery technologies. The company's methodologies not only focus on medical advancements but also strive to improve patient experiences, safety, and tolerability when addressing complex medical conditions.

Looking Forward

The dedication exhibited by Tiziana's team is leading to exciting prospects in the clinical world, fostering hope for those affected by challenging health issues. The meaningful milestone at Nasdaq reinvigorates the company's mission to enhance medical outcomes through innovative therapies.

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company that is at the forefront of developing transformative therapies via advanced drug delivery technologies. By advancing its intranasal delivery methods, Tiziana aims to outstrip traditional intravenous therapies, bringing novel immunomodulatory solutions to patients in need of effective treatments.

Company Contact Information

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: info@tizianalifesciences.com

Frequently Asked Questions

What was the significance of Tiziana Life Sciences ringing the Nasdaq Closing Bell?

It symbolizes Tiziana's advancements in biopharmaceutical therapies and recognizes the commitment of its team and investors towards innovative health solutions.

What is intranasal foralumab?

Intranasal foralumab is Tiziana's lead candidate, a fully human anti-CD3 monoclonal antibody aimed at improving the treatment of neurodegenerative diseases.

How is Tiziana Life Sciences addressing unmet medical needs?

The company focuses on developing innovative therapies that leverage unique drug delivery methods to enhance patient outcomes in challenging medical areas.

Are there any ongoing clinical trials for Tiziana's therapies?

Yes, Tiziana is conducting a Phase 2 trial for Alzheimer's disease among other key studies targeting various neuroinflammatory conditions.

Where can I find more information about Tiziana Life Sciences?

More information can be found by visiting their official website at www.tizianalifesciences.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

VitalCore Pioneers Jail Behavioral Health Expansion

Updated Category News Views 4

The Big Move in Correctional Healthcare VitalCore Health Strategies has made an impressive move with the opening of a 60-bed Behavioral Health Unit at Shawnee County Jail in Topeka, Kansas. The unit, part of a $21 million expansion completed on August 24, is set to change the landscape for inmates needing mental health and substance use treatment. This isn't just a slap...

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 1

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
ABC Honors 2026 Spirit of the Heart Leaders

Updated Category News Views 2

Celebrating Champions of Cardiovascular Health In a world where accolades often feel as cold as the stock market after a crash, it’s heartening to see genuine recognition for those who are making actual, lasting impact. On October 3, 2026, the Association of Black Cardiologists (ABC) will hold its annual Spirit of the Heart Awards at none other than Cipriani Wall...

Continue Reading
Webinar Highlights Workforce Skills and AI Tools

Updated Category News Views 3

The Shift Towards Skills-Based Talent Development The labor market's in a whirl, folks. Employers are scrambling to adapt to rapid changes, chasing after 'skills intelligence' like it's going out of style. On September 24, University of Phoenix, with its band of partners including Jobs for the Future and Skillmore™, will dig into this very topic. This upcoming webinar...

Continue Reading
Alif Semiconductor Unveils StartKit for Edge AI MCU Fam

Updated Category News Views 3

Here's some clarity amidst the storm of buzzwords: Alif Semiconductor has rolled out something the market's been howling for—Edge AI that doesn't break the bank. It's less about slick press releases and more about real-world implications. We're talking accessibility with their dirt-cheap, small-form-factor StartKit platform for Ensemble and Balletto microcontrollers....

Continue Reading
RevSystems Joins Elite OpenAI Partner Network

Updated Category News Views 0

RevSystems Inks Deal with OpenAI Partner Network In the latest shuffle of the AI advisory deck, RevSystems just found itself elbowing into the exclusive OpenAI Partner Network. Based out of New York, RevSystems has carved a niche by spinning tech wizardry into tangible business results. Their new status as an OpenAI Select Partner puts them on a playing field where AI...

Continue Reading
IDX Expands, Enhances Team Amid 56% H1 Growth

Updated Category News Views 3

IDX's Aggressive Global Expansion Here's a tip from a trader who’s seen cycles rise and fall: watch the movers who're playing the long game, putting down roots worldwide while making headway in the data game. IDX has clearly mapped out this trajectory as evidenced by its recent grab in the global strategic communications ring. IDX's bustling around like a squirrel...

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 1

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Agroz's Big Leap: New Supply Deal in Malaysia

Updated Category News Views 1

Agroz Inc. Executes a Game-Changing Deal If anyone thought the ag tech players were sitting idle, think again. Agroz Inc., noted for their innovative controlled-environment agriculture, just inked a pivotal deal with Harvest Hive in Malaysia. It's not just a nod to expansion—it's a strategic leap into the big leagues. Picture this: Harvest Hive's sprawling 500-acre farm...

Continue Reading
Everpure Surges into the S&P 500: A Milestone Move

Updated Category News Views 10

Big Leagues Beckon: Everpure Enters the S&P 500 Another day, another dollar, but today ain't just any day for Everpure. They’re stepping up from the minor leagues and grabbing their spot in the illustrious S&P 500 lineup. We're talking about a milestone that every company dreams of, but few achieve—this ain't your regular Tuesday headline. Stock Market's Stamp of...

Continue Reading

Top 5 Most Recently Viewed Articles

Four Seasons Education Sees Notable Growth in First Half FY26

Updated Category News Views 138

Four Seasons Education Financial Results Overview Four Seasons Education (Cayman) Inc. (NYSE: FEDU), a provider of education and tourism-related services, has revealed its unaudited financial results for the first half of the fiscal year 2026, celebrating significant improvements across various metrics. Key Financial Highlights The company experienced a strong revenue...

Continue Reading
Balchem Corporation's Strong Q3 2025 Financial Report Insights

Updated Category News Views 165

Overview of Balchem Corporation's Q3 2025 Financial Performance Balchem Corporation (NASDAQ: BCPC) has recently showcased an impressive financial performance for its third quarter of fiscal 2025, revealing remarkable sales growth and significant earnings improvements. Third Quarter 2025 Financial Highlights For the third quarter ended September 30, 2025, Balchem reported...

Continue Reading
Exciting Opportunities: Formula 100's New Test Team Program

Updated Category News Views 132

Exciting Launch of the Formula 100 Test Team Program Formula 100, a leader in precision bike care products, is thrilled to announce its newly established Formula 100 Test Team. The launch took place during a dynamic event that celebrated all things cycling. The team's formation allows passionate riders to influence the future of bike care products, working closely with...

Continue Reading
Renewed Lease Agreement for La Méditerranée Supports Community Growth

Updated Category News Views 135

Renewed Commitment to Local Communities Recent developments around the Upper Fillmore Revitalization Project highlight the vitality of community-focused initiatives. La Méditerranée, a beloved local restaurant, has announced an exciting extension of its lease at its Fillmore Street location, ensuring its presence in the neighborhood through the summer of 2028. Support...

Continue Reading
Matson, Inc. Reports Exceptional Fourth Quarter Earnings

Updated Category News Views 75

Exceptional Financial Performance in Fourth Quarter Matson, Inc. announced impressive fourth quarter results for 2024, reporting earnings per share (EPS) of $3.80. This marks a noteworthy increase from the previous year. Full Year Review and Key Metrics For the entire year of 2024, the company achieved a full-year EPS of $13.93. Net income reached a remarkable $476.4...

Continue Reading